Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck & Co. Inc.

www.merck.com

Latest From Merck & Co. Inc.

BACE Hopes Finally Fizzle As Biogen/Eisai End Elenbecestat Alzheimer's Studies

Biogen investors cheered the end of the company’s investment in the Phase III studies due to an unfavorable risk-benefit ratio – a widely expected result for the last clinical BACE inhibitor program.

Clinical Trials Neurology

Keeping Track: US FDA Approvals For Ibsrela, Gvoke And Nucala; A BTD For Tepotinib

The latest drug development news and highlights from our US FDA Performance Tracker. 
US FDA Performance Tracker Approvals

Merck KGaA Says New Meds Will Add €2bn Sales

The German group believes its €2bn target of pipeline sales by 2022 is achievable. It is hoping for a healthy contribution from rare lung cancer drug tepotinib.

Strategy Clinical Trials

Moderna Edges Closer To Becoming A Mid-Stage Drug Development Company

The mRNA specialist outlined ambitious plans to bring a vaccine for cytomegalovirus to market during an R&D day after releasing positive Phase I data.

Research & Development Vaccines
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register